コビド後遺症は必ずしも運動の障害ではない(Post-COVID not necessarily a barrier to exercise)

ad

2024-04-04 カロリンスカ研究所(KI)

COVID後症状を抱える人々は、初期の観察から運動が有害である可能性があるとされていましたが、カロリンスカ研究所の研究者らが発表した研究では、COVID後でも運動を厳密に避ける必要はないことが示されました。研究では、COVID後症状の患者31人と診断を受けていない人々31人を比較し、異なるトレーニングセッションを実施した結果、COVID後症状の人々も同じように運動できることが分かりました。ただし、COVID後症状の人々は全般的に運動能力や筋力が低く、約62%が筋肉の変化である筋無力を患っていることも明らかになりました。したがって、研究者らはCOVID後の運動に関する推奨事項を見直す必要性を提唱しています。

<関連情報>

COVID後の患者における機能制限と運動不耐性:無作為クロスオーバー臨床試験 Functional Limitations and Exercise Intolerance in Patients With Post-COVID Condition:A Randomized Crossover Clinical Trial

Andrea Tryfonos, PhD; Kaveh Pourhamidi, MD, PhD; Gustav Jörnåker, MSc; et al
JAMA Network Open  Published:April 4, 2024
DOI:10.1001/jamanetworkopen.2024.4386

コビド後遺症は必ずしも運動の障害ではない(Post-COVID not necessarily a barrier to exercise)

Key Points

Question Do nonhospitalized patients experiencing post-COVID condition (PCC) have exaggerated postexercise symptoms after high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), and strength training (ST)?

Findings In this randomized crossover clinical trial of 31 patients with PCC and 31 matched control participants, the exercise response was largely comparable between groups, with no profound symptom exacerbation. Patients with PCC reported more muscle pain after HIIT and concentration problems after MICT and had lower aerobic capacity and less muscle strength; 62% showed myopathic signs.

Meaning The findings suggest that cautious exercise rehabilitation should be recommended to prevent further deconditioning among patients with PCC.

Abstract

Importance Many patients with post-COVID condition (PCC) experience persistent fatigue, muscle pain, and cognitive problems that worsen after exertion (referred to as postexertional malaise). Recommendations currently advise against exercise in this population to prevent symptom worsening; however, prolonged inactivity is associated with risk of long-term health deterioration.

Objective To assess postexertional symptoms in patients with PCC after exercise compared with control participants and to comprehensively investigate the physiologic mechanisms underlying PCC.

Design, Setting, and Participants In this randomized crossover clinical trial, nonhospitalized patients without concomitant diseases and with persistent (≥3 months) symptoms, including postexertional malaise, after SARS-CoV-2 infection were recruited in Sweden from September 2022 to July 2023. Age- and sex-matched control participants were also recruited.

Interventions After comprehensive physiologic characterization, participants completed 3 exercise trials (high-intensity interval training [HIIT], moderate-intensity continuous training [MICT], and strength training [ST]) in a randomized order. Symptoms were reported at baseline, immediately after exercise, and 48 hours after exercise.

Main Outcomes and Measures The primary outcome was between-group differences in changes in fatigue symptoms from baseline to 48 hours after exercise, assessed via the visual analog scale (VAS). Questionnaires, cardiopulmonary exercise testing, inflammatory markers, and physiologic characterization provided information on the physiologic function of patients with PCC.

Results Thirty-one patients with PCC (mean [SD] age, 46.6 [10.0] years; 24 [77%] women) and 31 healthy control participants (mean [SD] age, 47.3 [8.9] years; 23 [74%] women) were included. Patients with PCC reported more symptoms than controls at all time points. However, there was no difference between the groups in the worsening of fatigue in response to the different exercises (mean [SD] VAS ranks for HIIT: PCC, 29.3 [19.5]; controls, 28.7 [11.4]; P = .08; MICT: PCC, 31.2 [17.0]; controls, 24.6 [11.7]; P = .09; ST: PCC, 31.0 [19.7]; controls, 28.1 [12.2]; P = .49). Patients with PCC had greater exacerbation of muscle pain after HIIT (mean [SD] VAS ranks, 33.4 [17.7] vs 25.0 [11.3]; P = .04) and reported more concentration difficulties after MICT (mean [SD] VAS ranks, 33.0 [17.1] vs 23.3 [10.6]; P = .03) compared with controls. At baseline, patients with PCC showed preserved lung and heart function but had a 21% lower peak volume of oxygen consumption (mean difference: -6.8 mL/kg/min; 95% CI, -10.7 to -2.9 mL/kg/min; P < .001) and less isometric knee extension muscle strength (mean difference: -37 Nm; 95% CI, -67 to -7 Nm; P = .02) compared with controls. Patients with PCC spent 43% less time on moderate to vigorous physical activity (mean difference, -26.5 minutes/d; 95% CI, -42.0 to -11.1 minutes/d; P = .001). Of note, 4 patients with PCC (13%) had postural orthostatic tachycardia, and 18 of 29 (62%) showed signs of myopathy as determined by neurophysiologic testing.

Conclusions and Relevance In this study, nonhospitalized patients with PCC generally tolerated exercise with preserved cardiovascular function but showed lower aerobic capacity and less muscle strength than the control group. They also showed signs of postural orthostatic tachycardia and myopathy. The findings suggest cautious exercise adoption could be recommended to prevent further skeletal muscle deconditioning and health impairment in patients with PCC.

Trial Registration ClinicalTrials.gov Identifier: NCT05445830

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました